Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Up 269.6% in October

Vaccinex, Inc. (NASDAQ:VCNX) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 127,500 shares, an increase of 269.6% from the October 15th total of 34,500 shares. Based on an average daily volume of 92,300 shares, the short-interest ratio is presently 1.4 days. Currently, 9.1% of the company’s shares are short sold.

Vaccinex Price Performance

NASDAQ VCNX traded up $0.19 on Thursday, reaching $3.65. The company had a trading volume of 87,671 shares, compared to its average volume of 55,441. The firm has a market cap of $6.30 million, a price-to-earnings ratio of -0.06 and a beta of 0.98. Vaccinex has a fifty-two week low of $1.39 and a fifty-two week high of $13.16. The business has a 50 day moving average of $3.59 and a two-hundred day moving average of $5.17.

Vaccinex (NASDAQ:VCNX) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($3.10) earnings per share for the quarter. The firm had revenue of $0.23 million during the quarter.

Institutional Trading of Vaccinex

A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC lifted its position in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,958 shares of the company’s stock after buying an additional 50,593 shares during the quarter. AIGH Capital Management LLC owned about 6.90% of Vaccinex worth $707,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 50.11% of the company’s stock.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.